News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tetragenetics, Inc. Announces New Collaboration in SionX™ Technology


4/3/2013 10:53:52 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tetragenetics Inc., a 2012 Gates Foundation Phase II grant recipient, and an emerging biotechnology company engaged in the development of particle-based vaccines and expression of ion channel drug targets, reported today that it has entered into a collaboration agreement with an option for an exclusive license with Pfizer (NYSE: PFE). Dr. Ted Clark, Founder and Chief Scientific Officer of Tetragenetics said, “Having large biopharmaceutical partners recognize the potential value of our technology to solve well-known protein expression problems for commercially relevant targets is important recognition of our pioneering science.”

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES